



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R<sup>1</sup> is            1) -CN,  
                      2) -NO<sub>2</sub>,  
                      3) a halogen, or  
                      4) (C<sub>1</sub>-C<sub>4</sub>)-alkyl-C(O)-OH;
- R<sup>2</sup> is            1) -CF<sub>3</sub>,  
                      2) a halogen, or  
                      3) -CN;
- R<sup>3</sup> is            1) =O,  
                      2) =S or  
                      3) =NH;
- X is              1) a radical of formula II




or

- 2) a radical of formula III



or X and Y together form a group of formula IV



FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com


in which R<sup>4</sup> is

- 1) hydrogen atom,
- 2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,
- 3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or
- 4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V



in which:

R<sup>5</sup> is, independently of R<sup>6</sup>, a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

wherein the alkyl is unsubstituted or mono- to tetrasubstituted by

halogens, and R<sup>6</sup> is, independently of R<sup>5</sup>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
- b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP


1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

- B2 Contd*
- COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4,  
5, or 6,  
c) -COOH,  
d) -CN, or  
e) -CF<sub>3</sub>, or  
2) a radical of formula VI,



in which R<sup>4</sup> is as defined above; and

- Z is 1) -O- or  
2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of  
said composition to a skin surface.


- B2 Sub C*
22. (Amended) A process for making a product for treatment of androgenic  
alopecia, comprising the step of forming said product by bringing together:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

d) a compound of the formula I




*B2  
cont*  
or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R<sup>1</sup> is      1) -CN,  
                  2) -NO<sub>2</sub>,  
                  3) a halogen, or  
                  4) (C<sub>1</sub>-C<sub>4</sub>)-alkyl-C(O)-OH;

- R<sup>2</sup> is      1) -CF<sub>3</sub>,  
                  2) a halogen, or  
                  3) -CN;

- R<sup>3</sup> is      1) =O,  
                  2) =S, or  
                  3) =NH;

- X is      1) a radical of formula II




or


- 2) a radical of formula III

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com



or X and Y together form a group of formula IV




in which R<sup>4</sup> is

- 1) hydrogen atom,
- 2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,
- 3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or
- 4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V



in which:

R<sup>5</sup> is, independently of R<sup>6</sup>, a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

wherein the alkyl is unsubstituted or mono- to tetrasubstituted by


halogens, and R<sup>6</sup> is, independently of R<sup>5</sup>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

B2  
Cont

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP


1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

- B2  
Cont*
- a) halogens,
  - b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4, 5, or 6,
  - c) -COOH,
  - d) -CN, or
  - e) -CF<sub>3</sub>, or
- 2) a radical of formula VI,



in which R<sup>4</sup> is as defined above; and

- Z is 1) -O- or  
2) a radical of formula VII




wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

23. (Amended) A process for making a product intended for treatment of seborrhea or acne, comprising the step of forming said product by bringing together:

- a) at least one physiologically tolerated film-forming agent;

- b) at least one physiologically tolerated solvent;  
c) at least one plasticizer; and  
d) a compound of the formula I




or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- R<sup>1</sup> is      1) -CN,  
                2) -NO<sub>2</sub>,  
                3) a halogen, or  
                4) (C<sub>1</sub>-C<sub>4</sub>)-alkyl-C(O)-OH;

- R<sup>2</sup> is      1) -CF<sub>3</sub>,  
                2) a halogen, or  
                3) -CN;

- R<sup>3</sup> is      1) =O,  
                2) =S, or  
                3) =NH;

- X is      1) a radical of formula II




FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP


1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

or

- 2) a radical of formula III



or X and Y together form a group of formula IV




in which R<sup>4</sup> is

- 1) hydrogen atom,
- 2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,
- 3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or
- 4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 4.4 -ON, or
- 4.5 -SH:

Y is 1) a radical of formula V




in which:

R<sup>5</sup> is, independently of R<sup>6</sup>, a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,

wherein the alkyl is unsubstituted or mono- to tetrasubstituted by


halogens, and R<sup>6</sup> is, independently of R<sup>5</sup>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the alkyl is unsubstituted or mono- to trisubstituted, by

- B2  
contd*
- a) halogens,
  - b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or mono- to trisubstituted, independently of one another, by -COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4, 5, or 6;
  - c) -COOH,
  - d) -CN, or
  - e) -CF<sub>3</sub>, or
- 2) a radical of formula VI,



in which R<sup>4</sup> is as defined above; and

- Z is 1) -O- or  
2) a radical of formula VII



wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.


FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

B3  
Subh C1

28. (Amended) A process for treatment of seborrhea or acne, comprising the step of applying to a patient in need or desire thereof a composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I



or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

R<sup>1</sup> is      1) -CN,  
                  2) -NO<sub>2</sub>,  
                  3) a halogen, or  
                  4) (C<sub>1</sub>-C<sub>4</sub>)-alkyl-C(O)-OH;


R<sup>2</sup> is      1) -CF<sub>3</sub>,  
                  2) a halogen, or  
                  3) -CN;

R<sup>3</sup> is      1) =O,  
                  2) =S, or  
                  3) =NH;

X is      1) a radical of formula II

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com




or

- 2) a radical of formula III



or X and Y together form a group of formula IV




in which R<sup>4</sup> is

- 1) hydrogen atom,
- 2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,
- 3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or
- 4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is 1) a radical of formula V



FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP


1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)

*B3*  
*Cont*

in which:


R<sup>5</sup> is, independently of R<sup>6</sup>, a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
wherein the alkyl is unsubstituted or mono- to tetrasubstituted by  
halogens, and R<sup>6</sup> is, independently of R<sup>5</sup>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the  
alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
  - b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or  
mono- to trisubstituted, independently of one another, by  
-COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4,  
5, or 6,
  - c) -COOH,
  - d) -CN, or
  - e) -CF<sub>3</sub>, or
- 2) a radical of formula VI,



in which R<sup>4</sup> is as defined above; and

- Z is
- 1) -O- or
  - 2) a radical of formula VII




FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

wherein said compound of formula I is released from the film formed by application of said composition to a skin surface.

*B3  
cont*  
29. (Amended) A cosmetic composition comprising:

- a) at least one physiologically tolerated film-forming agent;
- b) at least one physiologically tolerated solvent;
- c) at least one plasticizer; and
- d) a compound of the formula I




or a stereoisomeric form or a physiologically tolerated salt of any of the foregoing, in which:

- |                   |  |
|-------------------|--|
| R <sup>1</sup> is | 1) -CN,<br>2) -NO <sub>2</sub> ,<br>3) a halogen, or<br>4) (C <sub>1</sub> -C <sub>4</sub> )-alkyl-C(=O)-OH; |
| R <sup>2</sup> is | 1) -CF <sub>3</sub> ,<br>2) a halogen, or<br>3) -CN;   |
| R <sup>3</sup> is | 1) =O,<br>2) =S, or  |


FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
[www.finnegan.com](http://www.finnegan.com)


- X is
- 3) =NH;
  - 1) a radical of formula II



- or
- 2) a radical of formula III



or X and Y together form a group of formula IV



in which R<sup>4</sup> is


- 1) hydrogen atom,
- 2) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,
- 3) (C<sub>2</sub>-C<sub>6</sub>)-alkenyl-, or
- 4) (C<sub>1</sub>-C<sub>6</sub>)-alkyl-,

wherein the alkyl is mono- to trisubstituted by

- 4.1 -OH,
- 4.2 halogens,
- 4.3 -O-(C<sub>1</sub>-C<sub>4</sub>)-alkyl,
- 4.4 -CN, or
- 4.5 -SH;

Y is

- 1) a radical of formula V



B3  
Cont

FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com

*B3*  
*Cont*

in which:


R<sup>5</sup> is, independently of R<sup>6</sup>, a hydrogen atom or (C<sub>1</sub>-C<sub>4</sub>)-alkyl,  
wherein the alkyl is unsubstituted or mono- to tetrasubstituted by  
halogens, and R<sup>6</sup> is, independently of R<sup>5</sup>, (C<sub>1</sub>-C<sub>4</sub>)-alkyl, wherein the  
alkyl is unsubstituted or mono- to trisubstituted, by

- a) halogens,
  - b) phenyl-(CH<sub>2</sub>)<sub>m</sub>-, wherein the phenyl is unsubstituted or  
mono- to trisubstituted, independently of one another, by  
-COOH, -CN, or -CF<sub>3</sub>, and m is the integer zero, 1, 2, 3, 4,  
5, or 6,
  - c) -COOH,
  - d) -CN, or
  - e) -CF<sub>3</sub>, or
- 2) a radical of formula VI,



in which R<sup>4</sup> is as defined above; and

- Z is
- 1) -O- or
  - 2) a radical of formula VII



FINNEGAN  
HENDERSON  
FARABOW  
GARRETT &  
DUNNER LLP

1300 I Street, NW  
Washington, DC 20005  
202.408.4000  
Fax 202.408.4400  
www.finnegan.com